Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal adenocarcinoma. Three hundred and sixty-nine pati...
Main Authors: | Bramhall, SR, Hallissey, M, Whiting, J, Scholefield, J, Tierney, G, Stuart, R, Hawkins, R, McCulloch, P, Maughan, T, Brown, P, Baillet, M, Fielding, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
A phase II trial of marimastat in advanced pancreatic cancer.
by: Evans, J, et al.
Published: (2001) -
Labeling and enrichment of Arabidopsis thaliana matrix metalloproteases using an active-site directed, marimastat-based photoreactive probe.
by: Lenger, J, et al.
Published: (2012) -
Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity.
by: Yu, M, et al.
Published: (2013) -
The role of surgery in patients with advanced gastric cancer.
by: McCulloch, P
Published: (2006) -
Gastric cancer recurrence: Is it influenced by laparoscopic gastrectomy
by: McCulloch, P
Published: (2012)